The International Herald Tribune profiles Steven Nissen , the Cleveland Clinic scientist best known for his early warnings about the safety of Vioxx, long before the drug was taken off the market.
Merck Seeks FDA OK For Vioxx Successor
The FDA will soon make a decision on Merck's drug, Arcoxia, seen as a successor to its withdrawn drug Vioxx. A panel of government advisers has said that the drug should not be approved if safer alternatives are available.
Crusading Law Firm Doubles Presence in Macklowe's Tower 56
Mark Lanier, the 47-year-old attorney who litigated his way to CNBC fame by taking on Merck’s dreaded Vioxx, and who’s now representing sugar-cane farmers in their suit against Splenda, is doubling the size of his footprint in Harry Macklowe ’s Tower 56 . Mr. read more »
Merck profit plunges 58% on higher costs
Results were impacted by slew of charges for restructuring costs, an acquisition and increased legal reserves, mainly for Vioxx.
Contact:
Copyright © 2005 Vioxx Advisor.com All Rights Reserved